Trial Profile
1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Mar 2016 New trial record